A utonomic nervous system testing is used to document diabetic autonomic failure. Diabetic autonomic failure is defined as impaired function of the peripheral autonomic nervous system and can be divided into two categories: 1) autonomic neuropathy, in which there is a structural lesion of the peripheral autonomic neuron and 2) functional autonomic failure, in which no known structural lesion occurs. In addition to the classic neurotransmitters (acetylcholine and norepinephrine), newer neurotransmitters and neuromodulators such as substance P, neuropeptide K, calcitonin gene-related peptide, and nitric oxide are also involved. Also, the adrenal medullae are an integral part of the autonomic nervous system. With these caveats, the following definition is proposed, wherein autonomic abnormalities are classified as structural or functional with further subdivisions based on the overt or subclinical nature of the disorder, the specific subdivisions of the autonomic nervous system, and the specific organ systems involved.
AUTONOMIC NEUROPATHY IN
DIABETES -In the setting of diabetes mellitus without other causes of autonomic neuropathy there is a structural lesion that comprises a diffuse disorder of small nerve fibers of the cholinergic, adrenergic, and peptidergic nervous systems. This may be further divided into: 1) subclinical-that which is diagnosed only by tests and 2) clinical-that which presents with symptoms or signs.
FUNCTIONAL AUTONOMIC FAILURE IN DIABETES-
Reduced autonomic responses not attributable to classic diabetic autonomic neuropathy also occur and cause clinically important problems. An example is hypoglycemiaassociated autonomic failure (HAAF; 1,2). HAAF is a recently described functional disorder without a known structural lesion characterized by selectively reduced adrenomedullary (epinephrine) and parasympathetic (pancreatic polypeptide) responses to a given degree of hypoglycemia. It is associated with the interrelated clinical syndromes of defective glucose counterregulation, hypoglycemia unawareness, and elevated glycemic thresholds for symptoms of and autonomic responses to hypoglycemia during effective intensive therapy, and with a high frequency of iatrogenic hypoglycemia. A further example of functional autonomic failure is the impairment of gastric emptying with severe hyperglycemia (3) .
TESTS OF AUTONOMIC FUNCTION -
The autonomic nervous system is usually tested by evaluating reflex arcs. A reflex arc involves a stimulus, a receptor, an afferent nerve, central processing, an efferent nerve and an endorgan response. In addition to the reflex arc, there are several synapses involved throughout the pathway and different neurotransmitters at each synaptic cleft. It is important that, where possible, the confounding variables, standardization of stimulus, and normal end-organ func-ADDRESS CORRESPONDENCE AND REPRINT REQUESTS TO DR. RICHARD KAHN, AMERICAN DIABETES ASSO-CIATION, 1660 DUKE STREET, ALEXANDRIA, VA 22314.
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tion be established before one elicits the reflex arc to test the autonomic nervous system.
Many organs are dually innervated. Innervation of parasympathetic and sympathetic pathways often work as a check and balance system. Therefore, where possible, the autonomic nervous system needs to be evaluated recognizing that the result may reflect a decrease in one pathway or an increase in another.
An ideal test should be simple, noninvasive, easy for the operator and subjects, reproducible, sensitive, relevant to known physiological functions, suitable for longitudinal evaluation, and specific. The confounding variables affecting the test should be fairly well delineated. Some of the current autonomic tests fulfill nearly all of these obligations.
Standardization of testing
To reduce great variability in assessing the autonomic nervous system, it is important to standardize the test where possible. It is known that eating, drinking coffee, smoking, volume status, upright posture, medicines, and exercise may affect the cardiovascular autonomic nervous system and, presumably, other autonomic nervous organ systems. Therefore, in an ideal situation, studies should be performed with the patient having had no acute illness for the preceding 48 h; unaccustomed vigorous exercise for 24 h, anticholinergic drugs (including antidepressants), antihistamines and over-the-counter cough and cold medications, 9 -a-fluorohydrocortisone, diuretics, sympathomimetic and parasympathomimetic medications, and aspirin for 18 h; alcohol or hypoglycemic episodes for 12 h; or food, caffeine, or tobacco products for 8 h. Moreover, the studies should be performed in the morning in a quiet relaxed atmosphere. The patient should have been taught and practiced the procedure, and at the time of the study should not be wearing compressive clothing or Jobst stockings, should have the blood glucose stabilized DIABETES CARE, VOLUME 15, SUPPLEMENT 3, AUGUST 1992 
SPECIFIC SYSTEM INVOLVEMENT IN AUTONOMIC NEUROPATHY-
The functional changes associated with autonomic failure are given in Table 2 and the tests for autonomic failure in Table 3 .
Cardiovascular abnormalities
Testing for cardiovascular autonomic neuropathy involves a series of measurements.
1. Resting heart rate. 2. Beat-to-beat heart-rate variation. R-R variation is the magnitude of the sinus arrythmia and is measured by one of several methods (4): 1) standard deviation, 2) mean circular resultant, 3) maximal minus the minimal heart rate, 4) expiration-inspiration ratio, 5) Holter monitoring, and 6) power spectral analysis. R-R variation was considered to be exclusively under the control of the parasympathetic nervous system. However, subsequent studies demonstrate that both P-adrenergic stimulation (isoproterenol) (5) and 0-adrenergic blockade (propranolol) (6) decrease R-R variation. Both parasympathetic cholinergic blockade (atropine), and (3-adrenergic stimulation can nearly totally abolish R-R variation (5) . Thus, a small decrease in R-R variation results from sympathetic neuropathy or stress, whereas a large decrease in R-R variation can result from either parasympathetic neuropathy or stress (f$-adrenergic stimulation).
R-R variation is influenced by many physiological factors: a. Respiratory rate. There is a decrease in R-R variation with increasing respiration rate. The greatest R-R variation occurs at a respiratory rate of 5 breaths/ min. Thus, it is not only important to standardize the respiration rate, but the rate should be 5 breaths/min to optimize the results. b. Age. R-R variation decreases with age and allowance must be made for this. c. Weight. Parasympathetic activity is reduced in obese individuals.
d. Blood pressure/body temperature. These affect the response in predictable manners based on the heart-rate response. e. Heart rate. In normal individuals, heart rate increases and R-R variation decreases in a predictable manner with aging (7). In diabetic individuals, changes in heart rate are more complicated. With increasing duration of diabetes there is initially an increase followed by a slowing and finally a fixed heart rate (8). R-R variation, in contrast, decreases early and rapidly after the diagnosis of diabetes has been established (9). f. Position. Both standing and sitting significantly reduce R-R variation, therefore tests must be done in the lying position.
Confounding variables in R-R autonomic testing (4): a. General: this includes eating, drinking coffee, and smoking. b. Sodium salicylate raises the R-R variation. c. Dehydration can alter the response. d. Coronary artery disease: it has been shown that patients with inferior wall myocardial infarctions experience a bradycardiah y p o t e n s i v e s y n d r o m e , whereas patients with anterior wall myocardial infarctions experience tachycardia-hypertensive syndromes. Both can affect the R-R variation. Valsalva maneuver. The subject blows into the mouthpiece of a manometer to 40 mmHg for 15 s with continuous EKG monitoring before, during, and after the procedure. Healthy subjects develop tachycardia and peripheral vasoconstriction during strain, and an overshoot in blood pressure and bradycardia on release. The Valsalva ratio is the longest R-R/ shortest R-R. The Valsalva maneuver has also been well evaluated and studied (10) . It encompasses a complex reflex arc involving both sympathetic and parasympathetic pathways to the heart, sympathetic pathways to the vascular tree, and baroreceptors in the chest and lungs. 4. Blood pressure response to standing. The blood pressure response is measured with the patient lying supine at rest and again after 1 and 5 min standing. The absolute fall is arbitrary but fall in systolic blood pressure greater than 20 mmHg accompanied by symptoms of orthostasis is taken to be evidence of sympathetic failure. Photoplethysmographic beat-tobeat blood pressure recording may have significant advantages and can be used to evaluate the components of the Valsalva maneuver (11) . Its role in clinical studies awaits more extensive experience. 5. QTc interval. Examination of the EKG may reveal a prolonged QTc interval in patients with cardiac autonomic neuropathy (12, 13) .
Eye
Dark-adapted pupil size after total parasympathetic blockade may be a useful reproducible and valuable tool for evaluating autonomic nervous system function, and is related to poor dark vision (14) .
Motor disturbances of gastrointestinal tract
1. Esophageal and gallbladder enteropathy. These are usually discovered accidentally while reviewing upper gastrointestinal studies.
2. Gastroparesis. In evaluating a patient with suspected diabetic gastroparesis, the level of glycemic control should be assessed. Careful history of medications including DIABETES CARE, VOLUME 15, SUPPLEMENT 3, AUGUST 1992 ganglionic blocking agents and psychotropic drugs should be obtained. In addition, gastroduodenoscopy should be performed to exclude pyloric or other mechanical obstruction. After optimization of glycemic control, isotope scintigraphy to measure solid-phase gastric emptying times may be indicated (3).
3. Constipation. The extent of the evaluation in a diabetic patient complaining of constipation depends on the severity of the constipation and associated signs. All patients should have a digital examination to evaluate rectal sphincter tone. Other causes of constipation should be excluded. The ability of the bladder to empty urine not only depends on the ability of the detrusor to contract but also on a nonobstructed bladder outlet. Therefore, when evaluating the motor function of the bladder, it is necessary to rule out bladder outlet obstruction. This is particularly important in older men in whom bladder outlet obstruction is prevalent, i. Detrusor motor function can be studied by performing a cystometrogram (19, 20) . This test studies the detrusor reflex function. The normal bladder, when filled with fluid or gas, responds with a reflex contraction of the detrusor. This contraction can be voluntarily suppressed. A bladder that does not contract with filling is considered an areflexic bladder. This can be due to an inability to suppress the psychogenic central influence controlling this reflex, to neuropathy of sensor autonomic nerves, and/or to neuropathy of motor autonomic fibers responsible for contraction of the detrusor muscle. Therefore, the finding of bladder areflexia alone is not sufficient for the diagnosis of autonomic motor neuropathy of the bladder. The bethanechol supersensitivity test is used to determine the presence of efferent denervation of the bladder (21) . This test is based on Canon's law of denervation supersensitivity of an organ to its neurotransmitter. Bethanechol (5 mg), a muscarinic agonist, is given subcutaneously and the cystometrogram is repeated. After the bladder has been filled with 100 ml of water or gas, if the intravesical pressure is >20 cm H 2 O above the intravesical pressure before the administration of bethanechol, the test is considered positive. If motor autonomic neuropathy is present, the test will be positive. Patients with psychogenic suppression of the detrusor reflex or sensory autonomic neuropathy in the absence of motor neuropathy would have a negative test. The sensitivity of the test is not known. It is considered to be specific for autonomic motor neuropathy, but due to its invasive nature, it is probably not useful in longitudinal studies.
ii. Finally, measurement of volume of residual urine after urination may be used, in the absence of bladder outflow obstruction, as an indicator of bladder motor function. After the patient has urinated, the volume of residual urine can be determined non-invasively with an ultrasound bladder scanner or, invasively, by catheterization.
Sudomotor sympathetic function
Sudomotor function may be evaluated with the thermoregulatory sweat test, quantitative sudomotor axon reflex test, skin potentials, or sweat imprint quantitation. The thermoregulatory sweat test is a sensitive test of sweat distribution (22) . The subject is dusted with an indicator powder that turns purple when moist. This qualitative test can be rendered semiquantitative by charting the percentage of anterior body surface that is anhidrotic.
The skin potential can be recorded with standard EMG equipment from the palm and sole (23) . The stimulus is an electric shock, an inspiratory gasp, or other stimuli that activate type II and III mechanoreceptor afferents. The skin potential is readily evoked but habituates.
The silastic skin imprint is obtained after the application of silastic material to stimulated skin (24) . The sweat droplet indents the imprint and the count and diameter distribution can be determined. The usual stimulus is pilocarpine administered by iontophoresis. In the quantitative sudomotor axon reflex test the stimulus consists of the iontophoresis of acetylcholine via the stimulus compartment of a multicompartmental sweat cell (25, 26) . Postganglionic sympathetic nerve terminals are activated and the nerve impulse travels retrogradely, reaches a branch point, then travels orthogradely to activate a second population of sweat glands. The sweat response from this second population of sweat glands is recorded by a sudorometer. The stimulus compartment surrounds the central recording compartment, separated by an air gap and two ridges (to block diffusion). This test evaluates the integrity of the distal postganglionic sympathetic sudomotor axon. Four recording sites (distal forearm and 3 lower extremity sites) are used. The test has high sensitivity, a coefficient of variation of 20%, and, when used in conjunction with the thermoregulatory sweat test, defines the pre-or postganglionic site of the lesion. The test requires specialized equipment, trained technicians, and 20-30 min to complete.
Endocrine tests for functional autonomic failure in diabetes
HAAF appears to be distinct from classic diabetic autonomic neuropathy (27) .
First, the two disorders can occur independently. Second, deficient autonomic responses are specific for the stimulus of hypoglycemia in HAAF, whereas reduced sympathetic and parasympathetic responses to multiple stimuli characterize autonomic neuropathy. Third, whereas reduced epinephrine responses to hypoglycemia are a characteristic feature of HAAF, epinephrine responses are reduced little if at all in insulindependent diabetes mellitus (IDDM) with autonomic neuropathy compared with IDDM without autonomic neuropathy. Fourth, diabetic autonomic neuropathy, in sharp contrast to HAAF, is not a risk factor for iatrogenic hypoglycemia in IDDM (28, 29) . The pathogenesis of HAAF is not known; it probably is multifactorial and may be related to recent antecedent hypoglycemia (30) (31) (32) .
Tests for functional autonomic failure in IDDM are complex for the patient as well as the investigator and labor intensive. Ideally, both glycemic thresholds for symptoms and counterregulatory activation and glycemic defense against mild to moderate hyperinsulinemia should be determined in patients with IDDM and appropriate control subjects. Defense against hyperinsulincmic hypoglycemia is probably the more essential, at least for clinical purposes, because it has been shown in prospective studies (33, 34) to have clinical predictive power, i.e., to identify patients at markedly increased risk (> 25-fold) for severe iatrogenic hypoglycemia.
Glycemic thresholds can be defined with the hyperinsulinemic stepped hypoglycemic clamp technique (1,2,35) . The stepped hypoglycemic clamp technique can be highly standardized (1,2) . However, the test is complex. Precise quantitation of the glycemic thresholds requires both a euglycemic control clamp and a stepped hypoglycemic clamp in each individual studied. Arterialized blood samples are also required. The reproducibility of the stepped hypoglycemia clamp technique has not been assessed systematically. However, the fact that identical glycemic thresholds for symptoms and glucagon and epinephrine release were calculated from data generated with the technique in two different laboratories (1, 2) indicates that the test is probably reproducible. The technique is probably more suitable for populations rather than individuals, i.e., it might not identify all patients with minimally altered glycemic thresholds.
The results of the stepped hypoglycemia clamp test should be reported as absolute glycemic thresholds (glucose concentration), with those of the insulin infusion test as negative (adequate glucose counterregulation) or positive (defective glucose counterregulation). For the stepped hypoglycemic clamp technique, comparison of each response (symptom scores, hormone concentrations) of each individual patient with the 95% confidence interval of the corresponding response for a nondiabetic control group is preferable (1,2), although comparisons of group means can be used. For the latter, either parametric or nonparametric tests will be appropriate to a given data set.
Glycemic defense against hyperinsulinemia can be defined with an insulin infusion test (33) . The insulin infusion test can be standardized with a relatively low insulin infusion dose (0.67 mU • kg" 1 • min • -1 ) and a specific plasma glucose end point (<2 mM = defective glucose counterregulation). In addition, a neuroglycopenic end point must be included for ethical reasons. Inclusion of neuroglycopenia (difficulty thinking, blurred vision, dizziness, fatigue and faintness) as an additional end point increases the predictive power of the test (33) . Although the test yields only a positive or negative conclusion-defective or adequate glucose counterregulation-it has >90% clinical predictive power for development of hypoglycemia with intensive insulin treatment.
The test is labor intensive, requiring a minimum of two people (typically a physician and nurse); a third person is needed if cognitive function is assessed. It also requires accurate glucose measurements (e.g., with a Beckman or YSI analyzer not with a portable glucose monitor) at the bedside and the analytical capacity to perform the hormone measurements. Cognitive assessment generally requires a collaborating psychologist (2, 36) .
The insulin infusion test has been shown to be highly reproducible (33, 34) . With three replicate tests at 3-to 4-wk intervals, coefficients of variation for glucose and key counterregulatory hormone (glucagon, epinephrine) responses were <8% (34) . One can estimate sensitivity and specificity to be ~90% from the data of White et al. (33) . But, these are minimum estimates. In the data of Bolli et al. (34) , none of the patients with a negative test (nadir >2.2 mM) subsequently suffered severe clinical hypoglycemia, whereas all of those with a positive test (nadir <2.2 mM) suffered severe hypoglycemia during subsequent intensive therapy.
SUMMARY AND RECOMMENDATIONS-Several
organ systems can be monitored by reliable longitudinal testing. These include:
1. Cardiovascular system a. R-R variation b. Valsalva maneuver c. Postural blood pressure testing 2. Sudomotor a. Postganglionic function with QSART 3. Eye a. Dark-adapted pupil size after total parasympathetic blockade.
Specific research projects may include other tests but these tests do not lend themselves easily for large, multicenter type of studies. The test listed above are noninvasive, quantitative, and are sufficiently standardized to allow longitudinal assessment in diabetic patients. Furthermore, these tests allow evaluation of at least three different organ systems.
HAAF, an example of functional autonomic failure in diabetes, is best assessed by evaluation of the glycemic thresholds for epinephrine and pancreatic polypeptide secretion and hypoglycemic symptoms using a stepped hypoglycemic clamp protocol. The status of physiological defense against hyperinsulinemic hypoglycemia can be assessed with the insulin infusion test.
